TRIL Insider Trading Activity and SEC Form 4 Filings
TRIL insider trading summary
No open-market insider purchases or sales of Trillium Therapeutics Inc. (TRIL) have been reported on SEC Form 4 in the past 12 months.
Latest TRIL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 7, 2021 | Robert Uger | Chief Scientific Officer | Sell | $33K (3,646 @ $9.00) |
| Jun 7, 2021 | Robert Uger | Chief Scientific Officer | Sell | $30K (3,646 @ $8.27) |
| May 12, 2021 | Jan Skvarka | President and CEO | Sell | $220K (23,802 @ $9.24) |
| May 11, 2021 | Jan Skvarka | President and CEO | Sell | $982K (106,698 @ $9.20) |
| May 7, 2021 | Robert Uger | Chief Scientific Officer | Sell | $34K (3,646 @ $9.30) |
| Apr 8, 2021 | Penka Petrova | Chief Development Officer | Sell | $59K (5,312 @ $11.09) |
| Apr 7, 2021 | Robert Uger | Chief Scientific Officer | Sell | $39K (3,646 @ $10.82) |
| Mar 12, 2021 | Robert Uger | Chief Scientific Officer | Sell | $35K (2,917 @ $11.97) |
| Mar 10, 2021 | Penka Petrova | Chief Development Officer | Sell | $59K (5,312 @ $11.08) |
| Mar 8, 2021 | Robert Uger | Chief Scientific Officer | Sell | $37K (3,646 @ $10.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.